Overview

Safety and PK Study of BIBF 1120 in Japanese Patients With IPF

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To investigate safety of BIBF 1120 in Japanese patients with idiopathic pulmonary fibrosis (IPF), with and without pirfenidone background treatment. To assess pharmacokinetics of BIBF 1120 in Japanese patients, with and without pirfenidone background treatment. To assess pharmacokinetics of pirfenidone in Japanese patients, alone and in combination with BIBF 1120 treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Nintedanib